Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Debt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on Invested CapitalReturn on Sales

Dr Reddys Laboratories (RDY) Equity Average (2016 - 2023)

Historic Equity Average for Dr Reddys Laboratories (RDY) over the last 14 years, with Q3 2023 value amounting to $1.5 billion.

  • Dr Reddys Laboratories' Equity Average changed N/A to $1.5 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $1.5 billion, marking a year-over-year change of. This contributed to the annual value of $3.7 billion for FY2025, which is 1824.61% up from last year.
  • Dr Reddys Laboratories' Equity Average amounted to $1.5 billion in Q3 2023.
  • Over the past 5 years, Dr Reddys Laboratories' Equity Average peaked at $2.3 billion during Q4 2020, and registered a low of $956.9 million during Q1 2019.
  • Over the past 5 years, Dr Reddys Laboratories' median Equity Average value was $1.4 billion (recorded in 2022), while the average stood at $1.5 billion.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 1473146.44% in 2019, then skyrocketed by 698.65% in 2020.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Equity Average stood at $2.1 billion in 2019, then increased by 9.4% to $2.3 billion in 2020, then tumbled by 49.15% to $1.2 billion in 2021, then rose by 5.22% to $1.2 billion in 2022, then rose by 22.26% to $1.5 billion in 2023.
  • Its Equity Average was $1.5 billion in Q3 2023, compared to $1.5 billion in Q2 2023 and $1.2 billion in Q2 2022.